271
Participants
Start Date
March 31, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Omalizumab
Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Placebo
Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Alan Kaufman, MD, The Bronx
Maimonides Medical Center, Division of Pediatric Pulmonology, Brooklyn
Allergy Asthma Immunology of Rochester Research Center, Rochester
Asthma Allergy & Pulmonary Associates, Philadelphia
Chesapeake Clinical Research, Baltimore
Virginia Adult and Pediatric Allergy and Asthma PC, Richmond
Lynchburg Pulmonary Associates, Lynchburg
Allergy & Asthma Center of NC, PA, High Point
Wilmington Medical Research, Wilmington
Georgia Pollens Clinical Research Centers, Inc, Albany
Integrity Research, LLC, Pensacola
Palm Spring Research Institute, Inc, Hialeah
South Miami Clinical Research, LLC, South Miami
Innovative Research of West Florida, Inc, Clearwater
Hugh Windom, MD, PA, Sarasota
Jasper Summit Research, LLC, Jasper
Abraham Research, PLLC, Crescent Springs
Allergy and Respiratory Center, Canton
New Horizons Clinical Research, Cincinnati
Clinical Research Center of Indiana, Indianapolis
Respiratory Medicine Research Institute of Michigan, Ypsilanti
Clinical Research Institute, Minneapolis
Montana Medical Research, Inc., Missoula
Chest Medicine Clinical Services, Skokie
Sneeze, Wheeze and Itch Associates, LLC, Normal
The Clinical Research Center, LLC, St Louis
Kansas City Allergy & Asthma Center, Overland Park
Cotton-O'Neil Clinical Research Center, Topeka
Rx R&D, Metairie
Acadiana Medicine Clinic, Opelousas
Oklahoma Allergy & Asthma Clinic, Oklahoma City
Allergy, Asthma and Clinical Research Center, Oklahoma City
Pediatric Pulmonary Associates of North Texas, PA, Dallas
North Texas Institute for Clinical Trials, Fort Worth
Allergy & Asthma Associates, Houston
Western Sky Medical Research, El Paso
Medical Research of Arizona, A division of Allergy Asthma & Immunology Associates, LTD, Scottsdale
Waren W. Pleskow, MD, Encinitas
Allergy Associates Medical Group, Inc, San Diego
Pediatric Care Medical Group, Inc, Huntington Beach
Sansum Clinic, Santa Barbara
California Allergy & Asthma Medical Group, Palmdale
William Ebbeling, MD, Inc, Fresno
Allergy & Asthma Clinical Research, Inc., Walnut Creek
Baker Allergy Asthma and Dermatology Research Center, LLC, Lake Oswego
Asthma Inc., Seattle
Pulmonary and Research Associates, Spokane
Allergy Asthma and Immunology Center of Alaska, Anchorage
Paul A Shapero, MD, Bangor
AAPRI Clinical Research Institute, Lincoln
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Novartis Pharmaceuticals
INDUSTRY